The UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) have announced a new liaison programme. The agencies share that the roles aim to enhance day-to-day collaboration, support scientific exchange and enable
Pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced Skinvive by Juvéderm has received approval from the US Food and Drug Administration (FDA) to reduce neck lines. The company shares
The US Food and Drug Administration (FDA) has announced it will re-evaluate the regulatory status of several widely discussed therapeutic peptides, including BPC-157, KPV and Semax. Under current US compounding
Aesthetic pharmaceutical company Merz Aesthetics has received US Food and Drug Administration (FDA) approval for the treatment of wrinkles in the décolleté using regenerative biostimulator RADIESSE. The indication applies to
Pharmaceutical company Galderma has received approval from the US Food and Drug Administration (FDA) for the correction of temple hollowing using Restylane Contour. The company states that the approval is
The US Food and Drug Administration (FDA) has updated its guidance regarding how it regulates certain health-related technology. Under the revised guidance, a product may be classified as a general
The US Food and Drug Administration (FDA) has approved weight-loss drug Wegovy as the first once-daily oral GLP-1 weight-loss pill. The FDA approved the first oral GLP‑1 medication for chronic
The US Food and Drug Administration (FDA) has issued warnings to patients and healthcare providers after serious complications were reported from radiofrequency (RF) microneedling devices. According to the FDA, reported
The US Food and Drug Administration (FDA) has issued a new warning about finasteride, a drug commonly prescribed for androgenic alopecia. The agency highlighted potential risks of serious, long-term side
The US Food and Drug Administration (FDA) has approved Allergan Aesthetics’ Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe vertical platysma bands. The approval was supported by phase III clinical
